Therapix Biosciences (NSDQ:TRPX) said today that it inked a sublicense agreement for nasal drug delivery tech from Yissum Research Development Company at the Hebrew University.
According to the deal, Yissum plans to give Therapix an exclusive, global, sub-licensable, royalty-bearing license for its nasal delivery tech to be used with cannabinoids.
Get the full story at our sister site, Drug Delivery Business News.
The post Therapix, Yissum ink nasal drug delivery pact appeared first on MassDevice.